

## PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:

LEE, Sang-Yong

4F., Byukcheon Bldg., 1597-5, Seocho-dong, Seocho-gu,  
Seoul 137-876 Republic of Korea

PCT

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing  
(day/month/year) 20 JUNE 2005 (20.06.2005)

Applicant's or agent's file reference  
PCT05-009

FOR FURTHER ACTION

See paragraph 2 below

International application No.

PCT/KR2005/000266

International filing date (day/month/year)

28 JANUARY 2005 (28.01.2005)


Priority date (day/month/year)

International Patent Classification (IPC) or both national classification and IPC

IPC7 C07H 21/00

Applicant

KWON, Hyung-Joo et al



1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

## 2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  
For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/KR



Korean Intellectual Property Office  
920 Dunsan-dong, Seo-gu, Daejeon 302-701,  
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

JEONG Eui Jun

Telephone No.



**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2005/000266

**Box No. I Basis of this opinion**

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.  
  
☐ This opinion has been established on the basis of a translation from the original language into the following language \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
  - a. type of material  
☒ a sequence listing  
☐ table(s) related to the sequence listing
  - b. format of material  
☐ in written format  
☒ in computer readable form
  - c. time of filing/furnishing  
☒ contained in the international application as filed.  
☒ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority for the purposes of search.
3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2005/000266

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Claims	1 - 7	YES
	Claims	none	NO
Inventive step (IS)	Claims	none	YES
	Claims	1 - 7	NO
Industrial applicability (IA)	Claims	1 - 7	YES
	Claims	none	NO

**2. Citations and explanations :**

The following documents have been considered for the purpose of this written opinion :

D1 : Krieg A M : "CpG motifs in bacterial DNA and their immune effects" Annu. Rev. Immunol., vol. 20, (2002), page 709 - 760.

D2 : Krieg A M et al : "CpG motifs in bacterial DNA trigger direct B-cell activation" Nature, vol. 374, 6 April 1995, page 546 - 549.

**1. Novelty and Inventive Step**

The present invention relates to the oligodeoxynucleotides(ODN) for stimulating immune function, treating immune-related diseases and dermatitis, protecting normal immune cells against irradiation and balancing Th1/Th2 immune function.

D1 also discloses the oligodeoxynucleotides(ODN) containing CpG motifs activate host defense mechanism leading to innate and acquired immune responses. D1 discloses that these ODNs have the immunotherapeutic activities for immune-related diseases, cancer and allergic diseases. According to D1, the optimal CpG motifs for activating immune cells are purine-purine-CG-pyrimidine-pyrimidine such as GACGTT or GTCGTT.

The advanced technical features of the present application over the D1 is the various substitutions of flanked bases of CpG motif and outside bases from CpG motif. But D2 discloses that the substitution of flanked or outside bases can improve or reduce the activities of CpG motifs. So the addition or substitution of flanked and outside sequences of CpG motifs is merely one of several straightforward possibilities from which the skilled person would select, in accordance with circumstances, without the exercise of inventive skill, in order to solve the problem posed.

Therefore, claims 1 - 7 are considered to be novel [PCT Article 33(2)], but do not meet the requirements of inventive step [PCT Article 33(3)].

**2. Industrial Applicability**

The subject matter of claims 1- 7 is considered to be industrially applicable [PCT Article 33(4)].